CERo Therapeutics, Inc. Announces Publication Of Preclinical Research Supporting The Use Of Its Clinical Candidate CER-1236 To Treat AML Patients
Thursday, March 7, 2024 7:00 AM EDT
The paper details preclinical studies by CERo analyzing its lead clinical candidate CER-1236 in targeting Acute Myelogenous Leukemia (AML) tumor cells from human patients, and the candidate’s killing effects on these tumor cells.